





То:	Wombs Fertility & Reproductive Health Clinic- Pune					
	Datta Palace, Baner Rd, Shriram Society,					
	Lalit Estate, Baner,					
	Maharashtra					
	Pune - 411045					
	Contact:					
	Report Of: Mrs. TEJAL DAVE					
	Pt. Contact: 7774048870					

Sample ID	2100121890				
Patient ID	1002193138				
Received on	21/12/2021 13:05				
Registered on	25/12/2021 12:05				
Reported on	25/12/2021 13:17				
Referred by	DR.JAGRATI LAAD				
Sonography by	DR.VINIT MAHAJAN				

EVICOSCREEN - EVIDENCE BASED COMPREHENSIVE PRENATAL SCREENING REPORT

Patient Name: Mrs. TEJAL DAVE		Patient DOB: 18/11/1979
Ethnicity: <u>Asian</u>	City: PUNE	Hospital ID:
Sample Type: Serum		Risk assessment: Algorithm validated by SURUSS 2003, N.J Wald
Method: Time-resolved Fluroin	nmunoassay	

EVIC Screen is an evidence based prenatal screening program curated by Lilac Insights in accordance with the Fetal Medicine Foundation (UK) guidelines for First Trimester Screening to determine the probability of most common chromosomal aneuploidies in a pregnancy. It utilizes:

- Hormonal values from the pregnancy measured on Fetal Medicine foundation (UK) accredited analyzers and reagents
- Robust indigenous medians from over 5 lac+ pregnancies for different gestation ages
- $\bullet \ Risk \ calculations \ from \ evidence \ based \ algorithms \ validated \ through \ large \ international \ studies$
- External audit of the prenatal screening program by United Kingdom National External Quality Assessment Service (UKNEQAS) scheme and Randox International Quality Assessment Scheme (RIQAS)


RISK ASSESSMENT T21 (Down syndrome) 1: 100000 Low Risk **1: 100000** Low Risk T18 (Edwards' syndrome) 1:100000 1:100000 Low Risk Low Risk T13 (Patau syndrome) 1: 100000 Low Risk 1:100000 Low Risk MULTIPLE OF MEDIAN (MoM) PAPP-A Free ß-hCG 0.69 1.26

INTERPRETATION


The First Trimester Screening for the given sample is found **SCREEN NEGATIVE**.







Verified by **Mr. Pradip Kadam** Incharge Biochemistry



Verified by **Dr. Suresh Bhanushali**MD (Path), Consultant Pathologist









Patient name : Mrs. TEJAL DAVE

Sample ID : 2100121890

PREGNANCY DETAILS

No. of fetuses	: 2 DC	DA	E	DD	:06/07/2022	Age at Tern	n : 29.0) Years				
GA is Based on : Ass. rep.		L	.MP Date	:30/09/2021	LMP Certainty : Regular		ular					
Smoking: No	ne F	Parity :	ŀ	Height	:	Weight	: 64.0	00 Kg				
FHR :												
Pr	evious pregr	nancy histor	у	Pre-ec	lampsia history	Other findings						
Down sy	ndrome	Edwards' syı	ndrome	PE in pre	n previous pregnancy Insulin dependent diabetes			ent diabetes				
Patau sy	Patau syndrome NTD syndrome Pat. mother had PE Chronic hypertension											
Assisted Reproduction : Donor egg Transfer Date : 16/10/2021 Extraction Date : 25/09/2021 Donor DOB : 05/07/1993												
Note! Age at t	erm is calculate	ed from the Do	nor DOB									
EDD: Estimated Due Date GA: Gestation Age LMP: Last Menstrual Period FHR: Fetal Heart Rate NTD: Neural Tube Defect PE: Pre-eclampsia DOB: Date of Birth												
				SPECIMEN	DETAILS							
Sample ID	:210012	21890	CRL : 50.	7 mm	Test Name	Conc.	Unit	Corr. Mom				
Collection Da	ate : 20/12/2	2021	CRL2 :51.	8 mm	Free-ß-hCG	61.92	ng/mL	0.69				
Scan Date	:20/12/	2021	BPD :		NT	1.2	mm	0.90				
GA at Coll Da	GA at Coll Date :11 Weeks 5 Days BPD2 :				NT2		mm 0.81					
GA at Scan D	ate :11Wee	eks 5 Days	HC :		PAPP-A	5570.00	mU/L	1.26				
Received on	:21/12/2	2021	HC2 :									
GA: Gestation	Age CRL: Crown				Head Circumference fre		Human Cho	rionic Gonadotropin				
		NT: Nu	chal Translucen	ncy PAPP-A: Pre	gnancy-associated Plasm	na Protein-A						
				RISH	(S							
Disorder: Do	wn Syndrome					Result: Result:						
Tv	vin 1	Tν	vin 2			Twin 1		Twin 2				
Final risk:	1:100000	Final risk:	1:100000	Age risk:	1:896	Low Risk	Low	Risk				
Cutoff:	1:250	Cutoff:	1:250	Risk type	: Risk At Term							
Disorder: Edwards' Syndrome						Result:		Result:				
Twin 1 Twin 2						Twin 1		Twin 2				
Final risk:	1:100000	Final risk:	1:100000	Age risk:	1:4837	Low Risk	Low	Risk 🛑				
Cutoff:	1:100	Cutoff:	1:100	Risk type	: Risk At Term							
Disorder: Patau Syndrome						Result:		Result:				
Twin 1 Twin 2			vin 2			Twin 1		Twin 2				
Final risk:	1:100000	Final risk:	1:100000	Age risk:	1:14526	Low Risk	Low	Risk				
Cutoff:	1:100	Cutoff:	1:100	Risk type	: Risk At Term			_				











Patient name: Mrs. TEJAL DAVE Sample ID: 2100121890

PRENATAL SCREENING BACKGROUND

Every pregnant woman carries a certain degree of risk that her fetus/baby may have certain chromosomal defect/ abnormalities. Diagnosis of these fetal chromosomal abnormalities requires confirmatory testing through analysis of amniocytes or Chorionic Villous Samples (CVS). However, amniocentesis and CVS procedures carry some degree of risk for miscarriage or other pregnancy complications (Tabor and Alfirevic, 2010). Therefore in routine practice, prenatal screening tests are offered to a pregnant woman to provide her a personalised risk for the most common chromosomal abnormalities (T21-Down syndrome, T18- Edwards' syndrome, T13- Patau syndrome) using her peripheral blood sample. Based on this risk assessment, if the risk is high or intermediate, you can take informed decision of opting for invasive procedure such as amniocentesis or CVS followed by confirmatory diagnostic test(s), as per discussion with your clinician.

PRENATAL SCREENING TESTS ARE NOT CONFIRMATORY TESTS. THEY ARE LIKELIHOOD ASSESSMENT TESTS.

You may get your prenatal screening result as either of the following:-

High Risk

High Risk or Screen Positive Result: A High Risk Result does not mean that the pregnancy is affected with the condition. It means that the likelihood of the pregnancy having a condition is higher than the cut-off (Most commonly used cut-off is 1:250 and this represents the risk of pregnancy loss from confirmatory testing through CVS or amniocentesis).

Low Risk

Low Risk or Screen Negative Result: A Low Risk result does not mean that the pregnancy is not affected with a condition. It means that the likelihood of the pregnancy having a condition is lower than the cut-off.

Intermediate Risk **Intermediate Risk result:** An intermediate Risk result means that the pregnancy has an equivocal or a borderline risk of being affected with a condition. In this case, you may want to choose a second stage screening modality like an Integrated Screening Test that is done between 16 to 20 weeks of pregnancy or a Non-invasive Prenatal Screening Test between 12 to 20 weeks of pregnancy before taking a decision on an invasive confirmatory testing. This will help you improve the sensitivity of the screening test keeping an invasive test a last option were you to come as a high risk in the second stage screening test.

SIGNIFICANCE OF MULTIPLE OF MEDIANS (MoMs)

Prenatal Screening determines the likelihood of the pregnancy being affected with certain conditions by analysing levels of certain hormones. These hormones are Feto placental products (released by Fetus or placenta). Their levels not only indicate propensity of the fetus being affected with certain chromosomal conditions, they also provide indication of placental insufficiency that can potentially lead to pregnancy complications like Pre-Eclampsia or Intra-Uterine Growth Restriction. It is therefore important to take cognisance of the Reported MoMs alongside the Risk results.

For more information, visit our website at: www.lilacinsights.com/faq-pns

DISCLAIMERS

Limitations of the Test:

As prenatal screening tests are not confirmatory diagnostic tests, the possibility of false positive or false negative results can not be denied. The results issued for this test does not eliminate the possibility that this pregnancy may be associated with other chromosomal or sub- chromosomal abnormalities, birth defects and other complications.

Nuchal Translucency is the most prominent marker in screening for Trisomy 13, 18, 21 in the first trimester and should be measured in accordance with the Fetal Medicine Foundation (UK) guidelines. Nuchal Translucency or Crown Rump Length measurement, if not performed as per FMF (UK) imaging guidelines may lead to erroneous risk assessments and Lilac Insights bears no responsibility for errors arising due to sonography measurements not performed as per these criteria defined by international bodies such as FMF (UK), ISUOG.

It is assumed that the details provided along with the sample are correct. The manner in which this information is used to guide patient care is the responsibility of the healthcare provider, including advising for the need for genetic counselling or additional diagnostic testing like amniocentesis or Chorionic Villus Sampling. Any diagnostic test should be interpreted in the context of all available clinical findings. As with any medical test, there is always a chance of failure or error in sample analysis though extensive measures are taken to avoid these errors.

Note:

- $\bullet \quad \text{Quality of the Down syndrome screening program (Biochemical values, MoMs and Risk assessments) is monitored by UKNEQAS on an ongoing basis.}\\$
- This interpretation assumes that patient and specimen details are accurate and correct.
- Lilac Insights does not bear responsibility for the NT & CRL measurements. We strongly recommend that NT/ CRL measurements are performed as per FMF (UK)/ISUOG practice guidelines.
- It must be clearly understood that the results represent risk and not diagnostic outcomes. Increased risk does not mean that the baby is affected and further tests must be performed before a firm diagnosis can be made. A Low Risk result does not exclude the possibility of Down's syndrome or other abnormalities, as the risk assessment does not detect all affected pregnancies.

END OF REPORT



